Latest European Market News

International Graphite's March 2025 quarterly report highlights strong geopolitical tailwinds and government backing for its Springdale Graphite Project and Collie processing facilities, positioning the company as a key player in the critical minerals supply chain.

Little Green Pharma reported a robust 40% revenue increase for FY25, driven by strong European sales and the strategic acquisition of Health House. The company also advanced clinical research and secured new therapy funding, positioning itself for continued growth.

Castile Resources has added critical mineral bismuth as a by-product to its Rover 1 Bankable Feasibility Study, leveraging a dramatic price surge driven by Chinese export restrictions.

Elementos Limited has delivered a robust Definitive Feasibility Study for its Oropesa Tin Project in Spain, secured key partnerships, and commenced new drilling at its Cleveland Project in Tasmania, all against a backdrop of rising tin prices driven by global supply disruptions.

Medical Developments International reported a robust Q3 FY25 with $8.9 million revenue and $1.7 million operating cashflow, driven by strong Penthrox demand and pricing. New distribution agreements in France and Switzerland position the company for further European expansion.

GreenHy2 Limited reports a strategic push in Europe with new contracts for its advanced supercapacitor and hydrogen storage technologies, alongside a cash position of $814K and four quarters of funding runway.

Ionic Rare Earths has revealed preliminary Life Cycle Assessment results showing its magnet recycling process could reduce CO2 emissions by 30-50% compared to traditional rare earth oxide production, positioning the company as a sustainability leader in the UK and European rare earth supply chains.

Wellnex Life Limited has locked in A$9 million in conditional commitments to support its proposed dual listing on the London Stock Exchange’s AIM market, alongside launching a 1:1 entitlement offer for existing shareholders.

Memphasys has completed the final patient visit in its Felix™ clinical trial, with data lock expected within two weeks and preliminary results slated for early March 2025. This milestone paves the way for CE Mark submission and imminent commercialisation in Europe.

CSL Limited reported a solid half-year performance with 5% revenue growth and a 7% rise in net profit, driven by strong demand in its Behring and Vifor segments despite challenges in Seqirus. The company reaffirmed its full-year NPATA guidance of 10-13%, signaling confidence in its operational momentum.

CSL Limited posted a robust half-year performance with NPATA rising 5% at constant currency, driven by strong growth in CSL Behring and CSL Vifor despite challenges in its influenza vaccine segment. The company reaffirmed its FY25 guidance, anticipating double-digit earnings growth.

CSL Limited reported a solid 5% revenue increase and 6% rise in net profit after tax for the half year ended December 2024, underpinned by robust performance in its plasma therapies business despite headwinds in its influenza vaccine segment.